Regulation and maintenance of central nervous system (CNS) interstitial fluid homeostasis by the blood-brain barrier is largely the function of specialized cerebral capillary endothelial cells. In contrast to other vascular beds, the CNS capillary endothelium features continuous tight junctions and the absence of fenestrations or channels. Alterations in the blood-brain barrier occur commonly in diverse neurological conditions, including infectious and inflammatory processes, tumors, and even neurodegenerative diseases. Efforts to study the molecular pathobiology of disease-related blood-brain barrier alterations has been hampered by a paucity of well-characterized experimental models that could be manipulated to ask relevant mechanistic questions. In this issue, Coisne et al 1 report a novel in vitro murine blood-brain barrier model, which may advance these efforts. Murine cerebral capillaries were isolated and capillary endothelial cells were cocultured with syngenic astrocytes, oligodendroglia and microglia. In this system, brain capillary endothelial cells (MBCECs) formed differentiated monolayers, which retained many blood-brain barrier characteristics such as low permeability to small tracer molecules, high trans-endothelial electrical resistance, expression of P-glycoprotein, and an appropriate cell border distribution of tight junction proteins (claudin-5, occludin-1, claudin-3, Jam-1). To validate this coculture system in a disease model, the effect of endotoxin exposure on the expression of cell surface adhesion molecules was examined. The investigators show that the important mediators of neuroinflammation ICAM-1 and VCAM-1 were upregulated by brain capillary endothelial cells when treated with endotoxin similar to the in vivo situation. This model provides a new tool for understanding leukocyte-brain endothelial cell interactions and blood brain-barrier patholobiology. 
LOX may provide a key
In this issue of Lab Invest, Cuzzocrea et al 1 report that 5-lipoxygenase (LOX) knockout mice are protected from dinitrobenzene sulfonic acid-induced colitis relative to wild-type mice. This is an important observation because 5-lipoxygenase catalyzes the first step in leukotriene synthesis, the conversion of arachidonic acid to leukotriene A4. Given the central role of leukotrienes as inflammatory mediators, it is not surprising that neutrophil recruitment is blunted in 5-lipoxygenase knockout mice. Indeed, in other models of inflammatory diseases including experimental asthma, pneumonia, and encephalitis, 5-lipoxygenase knockout has been shown to reduce neutrophil infiltration. In the case of colitis, it is clear that leukotriene B4, which is synthesized by modification of leukotriene A4, is elevated in experimental trinitrobenzenesulfonic acid-induced colitis and that prostaglandin E2, which reduces colitis severity, also reduces mucosal leukotriene B4 levels. Moreover, 5-lipoxygenase inhibitors reduce mucosal leukotriene B4 levels as well as symptoms and histology damage in rodents and in patients with ulcerative colitis. Given the clinical implications of such therapy, it is important to understand the mechanisms by which 5-lipoxygenase inhibition, either pharmacological or genetic, ameliorates disease. Cuzzocrea et al have used both the lipoxygenase inhibitor zileuton and 5-lipoxygenase knockout mice to study events dependent on 5-lipoxygenase activity that lead to disease. They show that 5-lipoxygenase activity is necessary for both neutrophil migration in vitro and in vivo and suggest that the in vivo inhibition of neutrophil migration is partly mediated by blocking induction of P-selectin, E-selectin, ICAM-1, and VCAM-1 expression. Cuzzocrea et al 2 have made similar observations in experimental pancreatitis. Thus, therapeutic inhibition of 5-lipoxygenase may be the key to minimizing damage caused by neutrophil infiltration in colitis and other diseases.
